Article Text

Download PDFPDF
Definitive Radiotherapy for Treatment of Primary Vaginal Cancer: Effectiveness and Prognostic Factors
  1. Won Il Jang, MD, MS*,
  2. Hong-Gyun Wu, MD, PhD*,,,
  3. Sung Whan Ha, MD, PhD*,,§,
  4. Hak Jae Kim, MD, PhD*,,§,
  5. Soon Beom Kang, MD, PhD,
  6. Yong Sang Song, MD, PhD,§,
  7. Noh-Hyun Park, MD, PhD and
  8. Jae Weon Kim, MD, PhD,§
  1. * Departments of Radiation Oncology,
  2. Obstetrics and Gynecology, and
  3. Institute of Radiation Medicine, Medical Research Center, Seoul National University,
  4. § Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  1. Address correspondence and reprint requests to Hong-Gyun Wu, MD, PhD, Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehang-ro, Jongno-gu, Seoul 110-744, Republic of Korea. E-mail: wuhg{at}


Objective This study was performed to evaluate treatment outcomes and define prognostic factors for primary vaginal cancer treated with definitive radiotherapy.

Materials and Methods We retrospectively analyzed 38 patients with primary vaginal cancer who received radiotherapy with curative intent between January 1981 and August 2008. Of these 38 patients, 6 were excluded from this analysis because of other uncontrolled malignancy (n = 1), uncommon histology (n = 4), or insufficient medical records (n = 1). Twenty-three patients (72%) presented with early-stage disease (International Federation of Gynecology and Obstetrics stages 0, I, or II). Eleven patients (34%) were treated with external beam radiotherapy (EBRT) alone and 21 patients (66%) with EBRT plus brachytherapy (BT). Low–dose rate cesium-137 was used with intracavitary technique for most of the patients who received BT. Five patients received chemotherapy. The median total dose in patients who received EBRT and EBRT+BT was 50.4 Gy (range, 39.6–70.4 Gy) and 78.9 Gy (range, 72.0–87.0 Gy), respectively.

Results The median duration of follow-up was 38 months. Five-year overall survival, cause-specific survival, disease-free survival, local control, and regional control rates for the analyzed patients were 75%, 88%, 58%, 62% and 90%, respectively. Thirteen patients had treatment failure as follows: local (n = 7), distant (n = 1), local plus regional (n = 1), local plus distant (n = 2), and local plus regional plus distant (n = 2). Primary tumor size was a significant prognostic factor for disease-free survival (P = 0.039).

Conclusions Definitive radiotherapy is an effective treatment modality for primary vaginal cancer. Local failure was the major failure pattern, and achievement of local control is important for disease control and survival.

  • Vaginal cancer
  • Radiotherapy
  • Effectiveness
  • Prognostic factors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare that there are no conflicts of interest.